Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Ono Hooks Up with BMS, Clovis to Develop Opdivo/Rucaparib Combo Therapy in Japan, S. Korea, Taiwan
August 29, 2018
- I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
August 28, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- New AG Re-Pricing Rule Erodes 10 Billion Yen from Daiichi Sankyo Espha Sales
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
- Opdivo Price Cut Won’t Have Much Impact on Financial Results: Ono
August 27, 2018
- Pfizer, Astellas Move UP Completion Dates for 2 Xtandi Studies
August 24, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Lenvima Approved for 1st Line HCC Use in Europe: Eisai/Merck
August 24, 2018
- Shire Japan, Medipal Introduce Emergency Delivery System for Hemophilia Treatment
August 23, 2018
- MSD Launches Antibacterial Agent Sivextro
August 23, 2018
- Takeda, Ono Join Hands in Japan PIII for Opdivo-Cabozantinib Combo
August 23, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Otsuka Grabs Rights to Osaka Univ. CAR-T Therapy
August 22, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
- New Anti-Parkinson’s Drug Obtains POC in PIIa Study: Kyowa Kirin
August 21, 2018
- Japanese OTC Drug Market Grew 1.0% to 828 Billion Yen in 2017: Yano Research
August 21, 2018
- Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
August 21, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…